News

AKLRD and Nordic Bioscience announce collaboration



AKL Research and Development (AKLRD) and Nordic Bioscience Clinical Development, have announced a risk-share agreement to assess the efficacy of a novel, oral medicine, APPA, in a phase II trial of Osteoarthritis (OA). The collaboration was announced at the Osteoarthritis Research Society International (OARSI) World Congress 2019 in Toronto, Canada.  The partnership will assess the effectiveness of APPA both in relieving OA pain and in ...
Read More

An important milestone in the development of APPA



The Phase I clinical trial at Liverpool is designed to test the safety of APPA.  The first stage is now complete, and the clinical trial dose escalation committee has approved the transition from a single dose in healthy volunteers to multiple ascending 2 week dosing in osteoarthritis patients. In this part of a clinical trial, dose levels and frequency are chosen to achieve therapeutic drug levels and are maintained at steady state for 2 wee...
Read More

Dr Annalisa Jenkins and Lord Michael Grade as Advisors



AKL Research and Development (AKLRD), a company developing an investigational osteoarthritis (OA) medicine, announces the appointment of Dr Annalisa Jenkins and Lord Michael Grade as advisors. Dr Jenkins is former Head of Global Research & Development and Executive Vice President Global Development & Medical at Merck Serono. Lord Grade is former Chairman of the BBC. Current Chief Operating Officer (COO) of AKLRD David Miles has bee...
Read More

More weight loss tied to less knee pain for obese people



A recent article from Reuters Health has highlighted research by the American College of Rheumatology whose researchers have determined that obese people with knee osteoarthritis, a painful joint disease, may find greater symptom relief when they lose larger amounts of weight than when they shed fewer pounds, a recent study suggests. The researchers examined data on 240 obese adults with pain from knee osteoarthritis who were participating in an...
Read More

Phase I Clinical Trial at the University of Liverpool



The Phase I Clinical Trial to test AKL’s lead anti-inflammatory clinical candidate, APPA, as a potential new treatment for osteoarthritis is underway at the University of Liverpool Clinical Trials Unit. The trial has been approved for NIHR support. Osteoarthritis (OA) is the most common type of arthritis in the UK, affecting more than eight million people, and is the leading cause of joint pain and stiffness in older people. Improved func...
Read More

MHRA Approval for Formal Human Trials to Start



The University of Liverpool, as Sponsor of APPA's clinical program, has received clinical trial authorisation (CTA) from the MHRA (Medicines & Healthcare Products Regulatory Agency) to commence the Phase I clinical trial. The ongoing clinical program will test AKLRD’s lead candidate, APPA, as a potential new treatment for osteoarthritis. David Sharples, Chief Executive Officer at ALKRD Ltd, said "This is a huge achievement for AKLRD and ...
Read More

Under-exploited plants offer untold economic promise



A recent article in Nature by Ameenah Gurib Fakim, President of Mauritius and former Professor of Organic Chemistry, about the abundance of commercially available drugs that have their origins in plants. "Artemisinin, ginkgolides, quinine, reserpine, scopolamine, paclitaxel. What do these molecules have in common? They are all extracted from plants and transformed into useful drugs, treating conditions including malaria, nausea, cancer and hig...
Read More

AKLRD and APPA in the Press



Recently there have been various press reports on AKLRD's collaboration with Liverpool University on the clinical development of APPA. There has been coverage in both industry and mainstream press with Prof Rob Moots and Prof Steven Edwards being quoted extensively.     Pharma Times: Liverpool Uni leads clinical trial of promising osteoarthritis drug Drug Development Technology: Liverpool and AKLRD collaborate to evaluate APPA...
Read More